Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Cancer-killing viruses found safe but less effective than expected

Cancer-killing viruses found safe but less effective than expected

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of perifosine and temsirolimus shows promise against malignant glioma

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Repeated surgeries may improve survival for patients with glioblastomas

Repeated surgeries may improve survival for patients with glioblastomas

CSHL scientists discover new way to specifically target and kill cancer cells

CSHL scientists discover new way to specifically target and kill cancer cells

Human Gene Therapy articles describe two novel anti-tumor therapies

Human Gene Therapy articles describe two novel anti-tumor therapies

Glioblastoma multiforme can originate from cortical neurons

Glioblastoma multiforme can originate from cortical neurons

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

Recurrent glioblastoma: consider after effects before choosing palliative surgery

Recurrent glioblastoma: consider after effects before choosing palliative surgery

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Researchers identify many potential therapeutic targets for squamous cell lung cancers

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Patients tend to have worse outcomes when GBM appears in more than one location

Patients tend to have worse outcomes when GBM appears in more than one location

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.